Rift valley fever vaccine development, progress and constraints

Emerging Infectious Diseases

Volumn 17, Issue 9, 2011, Pages

  Kortekaas, Jeroen ^a   Zingeser, James ^b,c   de Leeuw, Peter ^c   de La Rocque, Stephane ^c,d   Unger, Hermann ^e   Moormann, Rob J M ^a  

^a WAGENINGEN UNIVERSITY   (Netherlands)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c FOOD AND AGRICULTURE ORGANIZATION OF THE UNITED NATIONS   (Italy)

^d CIRAD   (France)

^e INTERNATIONAL ATOMIC ENERGY AGENCY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; GLYCOPROTEIN; LIVE VACCINE; RIFT VALLEY FEVER VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANIMAL; ANIMAL DISEASE; ARTICLE; CONFERENCE PAPER; CONSENSUS; CONSENSUS DEVELOPMENT; DRUG SAFETY; HUMAN; IMMUNITY; IMMUNOGENICITY; IMMUNOLOGY; LIVESTOCK; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; ORGANIZATION; PREVENTION; REVACCINATION; RIFT VALLEY FEVER; RIFT VALLEY FEVER BUNYAVIRUS; SCIENTIST; VACCINE PRODUCTION; VIRUS LIKE AGENT; VIRUS STRAIN; WORKSHOP;

ANIMALS; CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; HUMANS; IMMUNOLOGY; PREVENTION AND CONTROL; RIFT VALLEY FEVER; RIFT VALLEY FEVER VIRUS; VACCINES, ATTENUATED; VETERINARY; VIRAL VACCINES;

EID: 80052178334     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1709.110506     Document Type: Article

References (19)

1. Smithburn KC. Rift Valley fever; the neurotropic adaptation of the virus and the experimental use of this modified virus as a vaccine. Br J Exp Pathol. 1949;30:1-16.
2. Morrill JC, Carpenter L, Taylor D, Ramsburg HH, Quance J, Peters CJ. Further evaluation of a mutagen-attenuated Rift Valley fever vaccine in sheep. Vaccine. 1991;9:35-41.
3. Morrill JC, Mebus CA, Peters CJ. Safety of a mutagen-attenuated Rift Valley fever virus vaccine in fetal and neonatal bovids. Am J Vet Res. 1997;58:1110-1114.
4. Morrill JC, Mebus CA, Peters CJ. Safety and efficacy of a mutagen-attenuated Rift Valley fever virus vaccine in cattle. Am J Vet Res. 1997;58:1104-1109.
5. Vialat P, Muller R, Vu TH, Prehaud C, Bouloy M. Mapping of the mutations present in the genome of the Rift Valley fever virus attenuated MP12 strain and their putative role in attenuation. Virus Res. 1997;52:43-50.
6. Hunter P, Erasmus BJ, Vorster JH. Teratogenicity of a mutagenised Rift Valley fever virus (MVP 12) in sheep. Onderstepoort J Vet Res. 2002;69:95-98.
7. Bird BH, Albarino CG, Hartman AL, Erickson BR, Ksiazek TG, Nichol ST. Rift Valley fever virus lacking the NSs and NSm genes is highly attenuated, confers protective immunity from virulent virus challenge, and allows for differential identification of infected and vaccinated animals. J Virol. 2008;82:2681-2691.
8. Bouloy M, Janzen C, Vialat P, Khun H, Pavlovic J, Huerre M, et al. Genetic evidence for an interferon-antagonistic function of Rift Valley fever virus nonstructural protein NSs. J Virol. 2001;75:1371-1377.
9. Dungu B, Louw I, Lubisi A, Hunter P, von Teichman BF, Bouloy M. Evaluation of the efficacy and safety of the Rift Valley fever clone 13 vaccine in sheep. Vaccine. 2010;28:4581-4587.
10. Muller R, Saluzzo JF, Lopez N, Dreier T, Turell M, Smith J, et al. Characterization of clone 13, a naturally attenuated avirulent isolate of Rift Valley fever virus, which is altered in the small segment. Am J Trop Med Hyg. 1995;53:405-411.
11. McElroy AK, Albarino CG, Nichol ST. Development of a RVFV ELISA that can distinguish infected from vaccinated animals. Virol J. 2009;6:125.
12. Soi RK, Rurangirwa FR, McGuire TC, Rwambo PM, DeMartini JC, Crawford TB. Protection of sheep against Rift Valley fever virus and sheep poxvirus with a recombinant capripoxvirus vaccine. Clin Vaccine Immunol. 2010;17:1842-1849.
13. Wallace DB, Ellis CE, Espach A, Smith SJ, Greyling RR, Viljoen GJ. Protective immune responses induced by different recombinant vaccine regimes to Rift Valley fever. Vaccine. 2006;24:7181-7189.
14. Kortekaas J, de Boer SM, Kant J, Vloet RP, Antonis AF, Moormann RJ. Rift Valley fever virus immunity provided by a paramyxovirus vaccine vector. Vaccine. 2010;28:4394-4401.
15. Kortekaas J, Dekker A, de Boer SM, Weerdmeester K, Vloet RP, de Wit AA, et al. Intramuscular inoculation of calves with an experimental Newcastle disease virus-based vector vaccine elicits neutralizing antibodies against Rift Valley fever virus. Vaccine. 2010;28:2271-2276.
16. Bhardwaj N, Heise MT, Ross TM. Vaccination with DNA plasmids expressing Gn coupled to C3d or alphavirus replicons expressing gn protects mice against Rift Valley fever virus. PLoS Negl Trop Dis. 2010;4:e725.
17. Lorenzo G, Martin-Folgar R, Hevia E, Boshra H, Brun A. Protection against lethal Rift Valley fever virus (RVFV) infection in transgenic IFNAR(-/-) mice induced by different DNA vaccination regimens. Vaccine. 2010;28:2937-2944.
18. Mandell RB, Koukuntla R, Mogler LJ, Carzoli AK, Freiberg AN, Holbrook MR, et al. A replication-incompetent Rift Valley fever vaccine: Chimeric virus-like particles protect mice and rats against lethal challenge. Virology. 2010;397:187-198.
19. Pichlmair A, Habjan M, Unger H, Weber F. Virus-like particles expressing the nucleocapsid gene as an efficient vaccine against Rift Valley fever virus. Vector Borne Zoonotic Dis. 2010;10:701-703.